CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - econpapers.repec.org
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - ui.adsabs.harvard.edu
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - ideas.repec.org
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
[PDF][PDF] CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - bookcafe.yuntsg.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR immune cells: design principles, resistance and the next generation.
L Labanieh, CL Mackall - Nature, 2023 - europepmc.org
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - pubmed.ncbi.nlm.nih.gov
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …